Concepedia

Kirsten Meid

KM

50

Publications

3.7K

Citations

27

H-Index

2013

Active since

Affiliations

Dana-Farber Cancer Institute(Current)

Harvard University

Boston University

Massachusetts General Hospital

Memorial Sloan Kettering Cancer Center

Kirsten Meid is an author at Dana-Farber Cancer Institute specializing in medicine, pathology, and immunology.

Top concepts

Publications per year

2013–2023

50

Publications

50

Ibrutinib in Previously Treated Waldenström’s Macroglobulinemia

Steven P. Treon, Christina Tripsas, Kirsten Meid et al. · New England Journal of Medicine · 2015 · 913 citations · Full text

The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19–infected patients

Steven P. Treon, Jorge J. Castillo, Alan P Skarbnik et al. · Blood · 2020 · 327 citations · Full text

Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenström's macroglobulinemia

Steven P. Treon, Christina Tripsas, Kirsten Meid et al. · Blood · 2014 · 177 citations · Full text

Ibrutinib Monotherapy in Symptomatic, Treatment-Naïve Patients With Waldenström Macroglobulinemia

Steven P. Treon, Joshua Gustine, Kirsten Meid et al. · Journal of Clinical Oncology · 2018 · 171 citations · Full text

Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenström Macroglobulinemia

Steven P. Treon, Kirsten Meid, Joshua Gustine et al. · Journal of Clinical Oncology · 2020 · 142 citations · Full text

Rows per page

1–5 of 50